Status:
UNKNOWN
Microwave Ablation Versus Liver Resection For Early Hepatocellular Carcinoma in Patients With Borderline Liver Function
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
We propose a randomized controlled study to compare the treatment efficacy of microwave ablation to liver resection for hepatocellular carcinoma (HCC) in patients with borderline liver function.
Detailed Description
Hepatocellular carcinoma (HCC) is a common cancer and is diagnosed at an earlier stage and with increasing frequency because of the wider implementation of screening programs. Whether liver resection ...
Eligibility Criteria
Inclusion
- Age \>18 years
- HCC amendable for both MWA and liver resection
- Liver function of ALBI Grade 2
- Tumour size \</= 5cm
- Absence of extrahepatic metastasis
- Absence of radiology evidence of major vascular or bile duct invasion
Exclusion
- Informed consent not available
- Patients with ALBI 3, Child-Pugh B or above
- Multifocal tumour
- Presence of portal vein or hepatic artery thrombosis
- Anticipation of concomitant procedures
- Emergency hepatectomy
- Ruptured HCC
- Patients with chronic renal failure
- Pregnant female patients
Key Trial Info
Start Date :
May 21 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT03766555
Start Date
May 21 2018
End Date
July 1 2025
Last Update
February 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Shatin, Hong Kong